Eignung von Angiotensin-II-Rezeptor(Typ AT1)-Antagonisten zur Anwendung bei Kindern
Die Entwicklung der Angiotensin-II-Rezeptor(Typ AT1)-Antagonisten (kurz AT1-Rezeptorantagonisten) geht auf die 1970-er und 80-er Jahre zurück. Die Stoffgruppe umfasst zurzeit sieben zugelassene Wirkstoffe (Losartan, Valsartan, Eprosartan, Irbesartan, Candesartan, Telmisartan und Olmesartan. Alle AT1...
Tác giả chính: | |
---|---|
Tác giả khác: | |
Định dạng: | Dissertation |
Ngôn ngữ: | Tiếng Đức |
Được phát hành: |
Philipps-Universität Marburg
2010
|
Những chủ đề: | |
Truy cập trực tuyến: | Bài toàn văn PDF |
Các nhãn: |
Thêm thẻ
Không có thẻ, Là người đầu tiên thẻ bản ghi này!
|
Angiotensin receptor antagonists were developed during the 1970th and 80th. In Germany there are seven labeled substances: losartan, valsartan, eprosartan, irbesartan, candesartan, telmisartan, olmesartan. They are all used for hypertension, some have additional indications like diabetic nephropathy or heart failure. In Europe there is no registration for children and adolescents younger than 18 years. In USA losartan and valsartan are labeled for children 6 years and older with primary hypertension. The most important clinical effects of the angiotensin receptor antagonists are lowering of systolic and diastolic blood pressure, antiproteinuric effects and amelioration of left ventricular hypertrophy. This article explores the efficacy and safety of angiotensin receptor antagonists in children and adolescents by means of a systematic review according to the standards of the Cochrane Collaboration. Beyond that a registry for children and adolescents with renal diseases in pre-terminal stages is developed and evaluated.